China Lays a Solid Foundation for Antitrust: Major Developments in 2021

Ting Wu of Haiwen & Partners reviews the regulatory reforms taking place in China’s life science and healthcare sector including legislation that has been released to encourage innovation and broaden market access to drugs, implementation of the patent linkage system, increasing antitrust enforcement pressure in the pharma sector, regulating medical devices, cosmetics and online hospitals.

Guo Yongmao of Haiwen & Partners discusses the various types of taxes under the PRC tax regime that new companies must consider when setting up a business in mainland China and highlights how tax impacts investors of a PRC company if they are foreign entities when considering dividends distribution, interest payment and transfer pricing

Both multinationals and domestic companies have already enacted changes to their internal policies and operations in response to China's new data and personal information processing requirements, from human resources management to customer privacy authorizations

Luka Groselj of Schellenberg Wittmer and Runyang Liu of Zhong Lun Law Firm provide practical guidance on contract drafting and performance to overcome possible non-signatory issues and how to navigate the current laws and court decisions when encountering such an issue